Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma (ALCI)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Texas Children's Hospital
The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine
Information provided by (Responsible Party):
Helen Heslop, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00062868
First received: June 17, 2003
Last updated: September 16, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: April 2018
  Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):